{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:21:49Z","timestamp":1793650909974,"version":"4.5.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Definition of the disease<\/jats:title>\n            <jats:p>AL amyloidosis results from extra-cellular deposition of fibril-forming monoclonal immunoglobulin (Ig) light chains (LC) (most commonly of lambda isotype) usually secreted by a small plasma cell clone. Most patients have evidence of isolated monoclonal gammopathy or smoldering myeloma, and the occurrence of AL amyloidosis in patients with symptomatic multiple myeloma or other B-cell lymphoproliferative disorders is unusual. The key event in the development of AL amyloidosis is the change in the secondary or tertiary structure of an abnormal monoclonal LC, which results in instable conformation. This conformational change is responsible for abnormal folding of the LC, rich in \u03b2 leaves, which assemble into monomers that stack together to form amyloid fibrils.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Epidemiology<\/jats:title>\n            <jats:p>AL amyloidosis is the most common type of systemic amyloidois in developed countries with an estimated incidence of 9 cases\/million inhabitant\/year. The average age of diagnosed patients is 65 years and less than 10% of patients are under 50.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical description<\/jats:title>\n            <jats:p>The clinical presentation is protean, because of the wide number of tissues or organs that may be affected. The most common presenting symptoms are asthenia and dyspnoea, which are poorly specific and may account for delayed diagnosis. Renal manifestations are the most frequent, affecting two thirds of patients at presentation. They are characterized by heavy proteinuria, with nephrotic syndrome and impaired renal function in half of the patients. Heart involvement, which is present at diagnosis in more than 50% of patients, leading to restrictive cardiopathy, is the most serious complication and engages prognosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnostic methods<\/jats:title>\n            <jats:p>The diagnosis relies on pathological examination of an involved site showing Congo red-positive amyloid deposits, with typical apple-green birefringence under polarized light, that stain positive with an anti-LC antibody by immunohistochemistry and\/or immunofluorescence. Due to the systemic nature of the disease, non-invasive biopsies such as abdominal fat aspiration should be considered before taking biopsies from involved organs, in order to reduce the risk of bleeding complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Differential diagnosis<\/jats:title>\n            <jats:p>Systemic AL amyloidosis should be distinguished from other diseases related to deposition of monoclonal LC, and from other forms of systemic amyloidosis. When pathological studies have failed to identify the nature of amyloid deposits, genetic studies should be performed to diagnose hereditary amyloidosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Management<\/jats:title>\n            <jats:p>Treatment of AL amyloidosis is based on chemotherapy, aimed at controlling the underlying plasma clone that produces amyloidogenic LC. The hematological response should be carefully checked by serial measurements of serum free LC. The association of an alkylating agent with high-dose dexamethasone has proven to be effective in two thirds of patients and is considered as the current reference treatment. New agents used in the treatment of multiple myeloma are under investigation and appear to increase hematological response rates. Symptomatic measures and supportive care is necessary in patients with organ failure. Noticeably, usual treatments for cardiac failure (i.e. calcium inhibitors, \u03b2-blockers, angiotensin converting enzyme inhibitors) are inefficient or even dangerous in patients with amyloid heart disease, that should be managed using diuretics. Amiodarone and pace maker implantation should be considered in patients with rhythm or conduction abnormalities. In selected cases, heart and kidney transplantation may be associated with prolonged patient and graft survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Prognosis<\/jats:title>\n            <jats:p>Survival in AL amyloidosis depends on the spectrum of organ involvement (amyloid heart disease being the main prognosis factor), the severity of individual organs involved and haematological response to treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1750-1172-7-54","type":"journal-article","created":{"date-parts":[[2012,8,21]],"date-time":"2012-08-21T14:20:43Z","timestamp":1345558843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":238,"title":["AL Amyloidosis"],"prefix":"10.1186","volume":"7","author":[{"given":"Estelle","family":"Desport","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bridoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Sirac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Delbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Quellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Goujon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lavergne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Touchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Fermand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Centre national de r\u00e9f\u00e9rence pour l\u2019amylose AL et les autres maladies par d\u00e9p\u00f4ts d\u2019immunoglobulines monoclonales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,21]]},"reference":[{"key":"412_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med. 2003, 349: 583-596. 10.1056\/NEJMra023144.","journal-title":"N Engl J Med"},{"key":"412_CR2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","volume":"79","author":"RA Kyle","year":"1992","unstructured":"Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O\u2019Fallon WM, Kurland LT: Incidence and natural history of primary systemic amyloidosis in Olmstead County, Minesota, 1950 through 1989. Blood. 1992, 79: 1817-1822.","journal-title":"Blood"},{"key":"412_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol. 2005, 79: 319-328. 10.1002\/ajh.20381.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"412_CR4","first-page":"48","volume":"17","author":"MA Gertz","year":"2010","unstructured":"Gertz MA, Merlini G: Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid. 2010, 17 (Suppl 1): 48-49.","journal-title":"Amyloid"},{"key":"412_CR5","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","volume":"29","author":"G Merlini","year":"2011","unstructured":"Merlini G, Seldin DC, Gertz MA: Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011, 29: 1924-1933. 10.1200\/JCO.2010.32.2271.","journal-title":"J Clin Oncol"},{"key":"412_CR6","first-page":"45","volume":"32","author":"RA Kyle","year":"1995","unstructured":"Kyle RA, Gertz MA: Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995, 32: 45-59.","journal-title":"Semin Hematol"},{"key":"412_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbapap.2005.08.014","volume":"1753","author":"L Obici","year":"2005","unstructured":"Obici L, Perfetti V, Palladini G, Moratti R, Merlini G: Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005, 1753: 11-22. 10.1016\/j.bbapap.2005.08.014.","journal-title":"Biochim Biophys Acta"},{"key":"412_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","volume":"29","author":"JH Pinney","year":"2011","unstructured":"Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, Sattianayagam PT, Gibbs SD, Orlandi E, Wassef NL, Bradwell AR, Hawkins PN, Gillmore JD: Outcome in renal AL amyloidosis after chemotherapy. J Clin Oncol. 2011, 29: 674-681. 10.1200\/JCO.2010.30.5235.","journal-title":"J Clin Oncol"},{"key":"412_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2214\/ajr.129.5.851","volume":"129","author":"L Ekelund","year":"1977","unstructured":"Ekelund L: Radiological findings in renal amyloidosis. Am J Roentgenol. 1977, 129: 851-853.","journal-title":"Am J Roentgenol"},{"issue":"50","key":"412_CR10","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jacc.2007.08.028","volume":"207","author":"JB Selvanayagam","year":"2007","unstructured":"Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S: Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007, 207 (50): 2101-2110.","journal-title":"J Am Coll Cardiol"},{"key":"412_CR11","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.amjmed.2011.04.013","volume":"124","author":"P Kappor","year":"2011","unstructured":"Kappor P, Thenappan T, Singh E, Kumar S, Greipp PR: Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med. 2011, 124: 1006-1015. 10.1016\/j.amjmed.2011.04.013.","journal-title":"Am J Med"},{"key":"412_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/hrt.2009.190405","volume":"97","author":"SW Dubrey","year":"2011","unstructured":"Dubrey SW, Hawkins PN, Falk RH: Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011, 97: 75-84. 10.1136\/hrt.2009.190405.","journal-title":"Heart"},{"key":"412_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3109\/13506129.2010.543443","volume":"18","author":"VR Loustaud-Ratti","year":"2011","unstructured":"Loustaud-Ratti VR, Cypierre A, Rousseau A, Yagoubi F, Abraham J, Fauchais AL, Carrier P, Lefebvre A, Bordessoule D, Vidal E, Sautereau D, Jaccard A: Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid. 2011, 18: 19-24.","journal-title":"Amyloid"},{"key":"412_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/MD.0b13e31816c43b6","volume":"87","author":"B Terrier","year":"2008","unstructured":"Terrier B, Jaccard A, Harousseau JL, Delarue R, Tournilhac O, Hunault-Berger M, Hamidou M, Dantal J, Bernard M, Grosbois B, Morel P, Coiteux V, Gisserot O, Rodon P, Hot A, Elie C, Leblond V, Fermand JP, Fakhouri F: The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine. 2008, 87: 99-109. 10.1097\/MD.0b13e31816c43b6.","journal-title":"Medicine"},{"key":"412_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00005792-197507000-00001","volume":"54","author":"RA Kyle","year":"1975","unstructured":"Kyle RA, Bayrd ED: Amyloidosis: review of 236 cases. Medicine. 1975, 54: 271-299.","journal-title":"Medicine"},{"key":"412_CR16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1053\/j.ajkd.2006.03.036","volume":"47","author":"C Sucker","year":"2006","unstructured":"Sucker C, Hetzel GR, Grabensee B, Stockschlaeder M, Scharf RE: Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis. 2006, 47: 947-955. 10.1053\/j.ajkd.2006.03.036.","journal-title":"Am J Kidney Dis"},{"key":"412_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/j.1538-7836.2007.02457.x","volume":"5","author":"B Bouma","year":"2005","unstructured":"Bouma B, Maas C, Hazenberg BP, Lokhorst HM, Gebbink MF: Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost. 2005, 5: 1139-1142.","journal-title":"J Thromb Haemost"},{"key":"412_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/13506120600876773","volume":"13","author":"ML Biewend","year":"2006","unstructured":"Biewend ML, Menke DM, Calamia KT: The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid. 2006, 13: 135-142. 10.1080\/13506120600876773.","journal-title":"Amyloid"},{"key":"412_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/13506120500351174","volume":"12","author":"M Paccalin","year":"2005","unstructured":"Paccalin M, Hachulla E, Cazalet C, Tricot L, Carreiro M, Rubi M, Grateau G, Roblot P: Localized amyloidosis: a survey of 35 French cases. Amyloid. 2005, 12: 239-245. 10.1080\/13506120500351174.","journal-title":"Amyloid"},{"key":"412_CR20","first-page":"218","volume":"84","author":"V Perfetti","year":"1999","unstructured":"Perfetti V, Vignarelli MC, Anesi E, Garini P, Quaglini S, Ascari E, Palladini G: The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica. 1999, 84: 218-221.","journal-title":"Haematologica"},{"key":"412_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa070484","volume":"357","author":"A Jaccard","year":"2007","unstructured":"Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP: My\u00e9lome Autogreffe (MAG) and Intergroupe Francophone du My\u00e9lome (IFM) Intergroup: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007, 357: 1083-1093. 10.1056\/NEJMoa070484.","journal-title":"N Engl J Med"},{"key":"412_CR22","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S0002-9440(10)64115-6","volume":"158","author":"V Perfetti","year":"2001","unstructured":"Perfetti V, Coluccia AM, Intini D, Malgeri U, Vignarelli MC, Casarini S, Merlini G, Neri A: Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol. 2001, 158: 1599-1603. 10.1016\/S0002-9440(10)64115-6.","journal-title":"Am J Pathol"},{"key":"412_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1365-2141.2003.04433.x","volume":"122","author":"HJ Lachmann","year":"2003","unstructured":"Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003, 122: 78-84. 10.1046\/j.1365-2141.2003.04433.x.","journal-title":"Br J Haematol"},{"key":"412_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1006\/jmbi.2000.3908","volume":"300","author":"LC Serpell","year":"2000","unstructured":"Serpell LC, Sunde M, Benson MD, Tennent GA, Pepys MB, Fraser PE: The protofilament substructure of amyloid fibrils. J Mol Biol. 2000, 300: 1033-1039. 10.1006\/jmbi.2000.3908.","journal-title":"J Mol Biol"},{"key":"412_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1006\/jmbi.1997.1348","volume":"273","author":"M Sunde","year":"1997","unstructured":"Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC: Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol. 1997, 273: 729-739. 10.1006\/jmbi.1997.1348.","journal-title":"J Mol Biol"},{"key":"412_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/clin.1994.1070","volume":"71","author":"S Ozaki","year":"1994","unstructured":"Ozaki S, Abe M, Wolfenbarger D, Weiss DT, Solomon A: Preferential expression of human \u03bb-light chain variable region subgroups in multiple myeloma, AL amyloidosis, and Waldenstr\u00f6m\u2019s macroglobulinemia. Clin Immunol Immunopathol. 1994, 71: 183-189. 10.1006\/clin.1994.1070.","journal-title":"Clin Immunol Immunopathol"},{"key":"412_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","volume":"119","author":"V Perfetti","year":"2012","unstructured":"Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, Obici L, Invernizzi R, Perlini S, Klersy C, Merlini G: The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012, 119: 144-150. 10.1182\/blood-2011-05-355784.","journal-title":"Blood"},{"key":"412_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.V98.3.714","volume":"98","author":"RL Comenzo","year":"2001","unstructured":"Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA: The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001, 98: 714-720. 10.1182\/blood.V98.3.714.","journal-title":"Blood"},{"key":"412_CR29","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1182\/blood-2002-09-2707","volume":"101","author":"RS Abraham","year":"2003","unstructured":"Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R: Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003, 101: 3801-3808. 10.1182\/blood-2002-09-2707.","journal-title":"Blood"},{"key":"412_CR30","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","volume":"107","author":"G Palladini","year":"2006","unstructured":"Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, D'Eril GM, Fogari R, Moratti R, Merlini G: Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006, 107: 3854-3858. 10.1182\/blood-2005-11-4385.","journal-title":"Blood"},{"key":"412_CR31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","volume":"94","author":"DA Brenner","year":"2004","unstructured":"Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, Liao R: Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004, 94: 1008-1010. 10.1161\/01.RES.0000126569.75419.74.","journal-title":"Circ Res"},{"key":"412_CR32","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R: Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010, 107: 4188-4193. 10.1073\/pnas.0912263107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"412_CR33","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/archinte.1983.00350080055015","volume":"143","author":"CA Libbey","year":"1983","unstructured":"Libbey CA, Skinner M, Cohen AS: Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med. 1983, 143: 1549-1552. 10.1001\/archinte.1983.00350080055015.","journal-title":"Arch Intern Med"},{"key":"412_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/dc.10370","volume":"30","author":"MA Ansari-Lari","year":"2004","unstructured":"Ansari-Lari MA, Ali SZ: Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinical useful test?. Diagn Cytopathol. 2004, 30: 178-181. 10.1002\/dc.10370.","journal-title":"Diagn Cytopathol"},{"key":"412_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1297-319X(02)00449-9","volume":"69","author":"E Hachulla","year":"2002","unstructured":"Hachulla E, Grateau G: Diagnostic tools for amyloidosis. Joint Bone Spine. 2002, 69: 538-545. 10.1016\/S1297-319X(02)00449-9.","journal-title":"Joint Bone Spine"},{"issue":"Suppl 1","key":"412_CR36","first-page":"151","volume":"17","author":"E Moumas","year":"2010","unstructured":"Moumas E, Desport E, Lacombe C, Gombert JM, Goujon JM, Bridoux F, Touchard G: Systemic AL amyloidosis with renal involvement in a region of Western France. Amyloid. 2010, 17 (Suppl 1): 151.","journal-title":"Amyloid"},{"key":"412_CR37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/MNH.0b013e3280bdc0db","volume":"16","author":"MM Picken","year":"2007","unstructured":"Picken MM: New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr Opin Nephrol Hypertens. 2007, 16: 196-203. 10.1097\/MNH.0b013e3280bdc0db.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"412_CR38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/134.4.545","volume":"134","author":"MM Picken","year":"2010","unstructured":"Picken MM: Amyloidosis-where are we now and where are we heading?. Arch Pathol Lab Med. 2010, 134: 545-551.","journal-title":"Arch Pathol Lab Med"},{"key":"412_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-94-017-0191-4_10","volume-title":"Monoclonal gammopathies and the kidney","author":"G Touchard","year":"2003","unstructured":"Touchard G: Ultrastructural pattern and classification of renal monoclonal immunoglobulin deposits. Monoclonal gammopathies and the kidney. Edited by: Touchard G, Aucouturier P, Hermine O, Ronco P. 2003, Kluwer Academic Publishers, Dordrecht, 95-117."},{"key":"412_CR40","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006, 354: 1362-1369. 10.1056\/NEJMoa054494.","journal-title":"N Engl J Med"},{"key":"412_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/01913120490430436","volume":"28","author":"R Veeramachaneni","year":"2004","unstructured":"Veeramachaneni R, Gu X, Herrera GA: Atypical amyloidosis: diagnostic challenges and the role of immunoelectron microscopy in diagnosis. Ultrastruct Pathol. 2004, 28: 75-82. 10.1080\/01913120490430436.","journal-title":"Ultrastruct Pathol"},{"key":"412_CR42","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","volume":"114","author":"JA Vrana","year":"2009","unstructured":"Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A: Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009, 114: 4957-4959. 10.1182\/blood-2009-07-230722.","journal-title":"Blood"},{"key":"412_CR43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.echo.2008.11.013","volume":"22","author":"GB Al-Zahrani","year":"2009","unstructured":"Al-Zahrani GB, Bellavia D, Pellikka PA, Dispenzieri A, Hayman SR, Oh JK, Miyazaki C, Miller FA: Doppler myocardial imaging compared to standard two-dimensional and Doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis. J Am Soc Echocardiogr. 2009, 22: 290-298. 10.1016\/j.echo.2008.11.013.","journal-title":"J Am Soc Echocardiogr"},{"key":"412_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","volume":"3","author":"IS Syed","year":"2010","unstructured":"Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M: Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010, 3: 155-164. 10.1016\/j.jcmg.2009.09.023.","journal-title":"JACC Cardiovasc Imaging"},{"key":"412_CR45","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004, 22: 3751-3757. 10.1200\/JCO.2004.03.029.","journal-title":"J Clin Oncol"},{"key":"412_CR46","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","volume":"116","author":"G Palladini","year":"2010","unstructured":"Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, Perlini S, Albertini R, Russo P, Foli A, Bragotti LZ, Obici L, Moratti R, Melzi d'Eril GV, Merlini G: The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010, 116: 3426-3430. 10.1182\/blood-2010-05-286567.","journal-title":"Blood"},{"key":"412_CR47","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1182\/blood-2010-02-267708","volume":"116","author":"AV Kristen","year":"2010","unstructured":"Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, Merkle C, Hardt S, Schnabel PA, R\u00f6cken C, Schonland SO, Ho AD, Dengler TJ, Katus HA: Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood. 2010, 116: 2455-2461. 10.1182\/blood-2010-02-267708.","journal-title":"Blood"},{"key":"412_CR48","first-page":"443","volume":"16","author":"PN Hawkins","year":"2003","unstructured":"Hawkins PN: Hereditary systemic amyloidosis with renal involvement. J Nephrol. 2003, 16: 443-448.","journal-title":"J Nephrol"},{"key":"412_CR49","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1681\/ASN.V1271482","volume":"12","author":"J Lin","year":"2001","unstructured":"Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D'Agati VD: Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001, 12: 1482-1492.","journal-title":"J Am Soc Nephrol"},{"key":"412_CR50","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2215\/CJN.08640811","volume":"7","author":"SH Nasr","year":"2012","unstructured":"Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D'Agati VD, Leung N: Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012, 7: 231-239. 10.2215\/CJN.08640811.","journal-title":"Clin J Am Soc Nephrol"},{"key":"412_CR51","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1172\/JCI115252","volume":"87","author":"JL Preud\u2019homme","year":"1991","unstructured":"Preud\u2019homme JL, Cogne M, Bauwens M, Touchard G, Aucouturier P: Structure of a monoclonal kappa chain of the VkappaIV subgroup in the kidney and plasma cells in light chain deposition disease. J Clin Invest. 1991, 87: 2186-2190. 10.1172\/JCI115252.","journal-title":"J Clin Invest"},{"key":"412_CR52","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","volume":"100","author":"M Skinner","year":"1996","unstructured":"Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, Jones LA, Cohen AS: Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996, 100: 290-298. 10.1016\/S0002-9343(97)89487-9.","journal-title":"Am J Med"},{"key":"412_CR53","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","volume":"336","author":"RA Kyle","year":"1997","unstructured":"Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM: A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997, 336: 1202-1207. 10.1056\/NEJM199704243361702.","journal-title":"N Engl J Med"},{"key":"412_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","volume":"140","author":"M Skinner","year":"2004","unstructured":"Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004, 140: 85-93.","journal-title":"Ann Intern Med"},{"key":"412_CR55","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","volume":"110","author":"V Sanchorawala","year":"2007","unstructured":"Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC: Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan an stem-cell transplantation. Blood. 2007, 110: 3561-3563. 10.1182\/blood-2007-07-099481.","journal-title":"Blood"},{"key":"412_CR56","first-page":"80","volume":"17","author":"SO Schonland","year":"2010","unstructured":"Schonland SO, Bochtler T, Perz J, et al: Results of two consecutive phase II trials of patients with systemic AL amyloidosis treated with high-dose melphalan after induction and mobilization chemotherapy [12th international symposium on amyloidosis abstracts]. Amyloid. 2010, 17: 80-81.","journal-title":"Amyloid"},{"key":"412_CR57","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","volume":"118","author":"MT Cibeira","year":"2011","unstructured":"Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M: Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011, 118: 4346-4352. 10.1182\/blood-2011-01-330738.","journal-title":"Blood"},{"key":"412_CR58","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2011-07-370031","volume":"119","author":"S Madan","year":"2012","unstructured":"Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA: High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012, 119: 1117-1122. 10.1182\/blood-2011-07-370031.","journal-title":"Blood"},{"key":"412_CR59","doi-asserted-by":"publisher","first-page":"880","DOI":"10.4065\/81.7.880","volume":"81","author":"DH Vesole","year":"2006","unstructured":"Vesole DH, P\u00e9rez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN: Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc. 2006, 81: 880-888. 10.4065\/81.7.880.","journal-title":"Mayo Clin Proc"},{"key":"412_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2141.2006.06204.x","volume":"134","author":"HJ Goodman","year":"2006","unstructured":"Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN: Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol. 2006, 134: 417-425. 10.1111\/j.1365-2141.2006.06204.x.","journal-title":"Br J Haematol"},{"key":"412_CR61","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","volume":"103","author":"G Palladini","year":"2004","unstructured":"Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G: Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004, 103: 2936-2938. 10.1182\/blood-2003-08-2788.","journal-title":"Blood"},{"key":"412_CR62","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","volume":"109","author":"AD Wechalekar","year":"2007","unstructured":"Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD: Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007, 109: 457-464. 10.1182\/blood-2006-07-035352.","journal-title":"Blood"},{"key":"412_CR63","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1182\/blood-2010-07-294405","volume":"116","author":"P Moreau","year":"2010","unstructured":"Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, Salles G, Leblond V, Roussel M, Alakl M, Hermine O, Planche L, Harousseau JL, Fermand JP: Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1\/2 dose-escalation study. Blood. 2010, 116: 4777-4782. 10.1182\/blood-2010-07-294405.","journal-title":"Blood"},{"key":"412_CR64","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G: Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010, 28: 1031-1037. 10.1200\/JCO.2009.23.8220.","journal-title":"J Clin Oncol"},{"key":"412_CR65","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","volume":"114","author":"DE Reece","year":"2009","unstructured":"Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Blad\u00e9 J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL: Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009, 114: 1489-1497. 10.1182\/blood-2009-02-203398.","journal-title":"Blood"},{"key":"412_CR66","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1182\/blood-2011-11-390930","volume":"119","author":"JR Mikhael","year":"2012","unstructured":"Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R: Cyclophosphamide-bortezomib-dexamethasone (CYBORD) produces rapid and complete hematological response in patients with AL amyloidosis. Blood. 2012, 119: 4398-4389.","journal-title":"Blood"},{"key":"412_CR67","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","volume":"119","author":"CP Venner","year":"2012","unstructured":"Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD: Cyclophosphamide, bortezomib and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression free survival. Blood. 2012, 119: 4387-Inday. 10.1182\/blood-2011-10-388462.","journal-title":"Blood"},{"key":"412_CR68","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","volume":"88","author":"RL Comenzo","year":"1996","unstructured":"Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH, Skinner M: Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood. 1996, 88: 2801-2806.","journal-title":"Blood"},{"key":"412_CR69","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","volume":"91","author":"RL Comenzo","year":"1998","unstructured":"Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998, 91: 3662-3670.","journal-title":"Blood"},{"issue":"Suppl 1","key":"412_CR70","first-page":"130","volume":"18","author":"H Landau","year":"2011","unstructured":"Landau H, Hassoun H, Bello C, Hoover E, Riedel ER, Nimer SD, Comenzo RL: Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid. 2011, 18 (Suppl 1): 130-131.","journal-title":"Amyloid"},{"key":"412_CR71","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2001.19.14.3350","volume":"19","author":"A Dispenzieri","year":"2001","unstructured":"Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Gertz MA: Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001, 19: 3350-3356.","journal-title":"J Clin Oncol"},{"key":"412_CR72","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2141.2008.07327.x","volume":"143","author":"D Lebovic","year":"2008","unstructured":"Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, Maurer MS, Steingart RM, Cohen AD, Comenzo RL: Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol. 2008, 143: 369-373. 10.1111\/j.1365-2141.2008.07327.x.","journal-title":"Br J Haematol"},{"key":"412_CR73","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3324\/haematol.12982","volume":"93","author":"MA Gertz","year":"2008","unstructured":"Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA: Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica. 2008, 93: 1402-1406. 10.3324\/haematol.12982.","journal-title":"Haematologica"},{"key":"412_CR74","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3816\/CLM.2009.n.020","volume":"9","author":"MA Gertz","year":"2009","unstructured":"Gertz MA, Hayman SR, Buadi FK: Transplantation for IgM amyloidosis and IgM myeloma. Clin Lymphoma Myeloma. 2009, 9: 77-79. 10.3816\/CLM.2009.n.020.","journal-title":"Clin Lymphoma Myeloma"},{"key":"412_CR75","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","volume":"109","author":"V Sanchorawala","year":"2007","unstructured":"Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007, 109: 492-496. 10.1182\/blood-2006-07-030544.","journal-title":"Blood"},{"key":"412_CR76","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","volume":"109","author":"A Dispenzieri","year":"2007","unstructured":"Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007, 109: 465-470. 10.1182\/blood-2006-07-032987.","journal-title":"Blood"},{"key":"412_CR77","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3324\/haematol.11325","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, Dimopoulos MA: Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007, 92: 1351-1358. 10.3324\/haematol.11325.","journal-title":"Haematologica"},{"key":"412_CR78","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3324\/haematol.11627","volume":"93","author":"AD Wechalekar","year":"2008","unstructured":"Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD: Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease. Haematologica. 2008, 93: 295-298. 10.3324\/haematol.11627.","journal-title":"Haematologica"},{"key":"412_CR79","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00277-010-1062-6","volume":"90","author":"W Lamm","year":"2011","unstructured":"Lamm W, Willenbacher W, Lang A, Zojer N, M\u00fcld\u00fcr E, Ludwig H, Schauer-Stalzer B, Zielinski CC, Drach J: Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol. 2011, 90: 201-206. 10.1007\/s00277-010-1062-6.","journal-title":"Ann Hematol"},{"key":"412_CR80","first-page":"746","volume":"114","author":"SV Zonder JA","year":"2009","unstructured":"Zonder JA SV, Snyder RM, Matous J, Terebelo H, Janakiraman N, Mapara MY, Lalo S, Tageja N, Webb C, Monsma D, Sellers C, Abrams J, Gasparetto C: Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in AL-amyloidosis with tolerable neurotoxicity. Blood (ASH Annual Meeting Abstracts). 2009, 114: 746.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"412_CR81","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.4065\/75.12.1264","volume":"75","author":"O Tirzaman","year":"2000","unstructured":"Tirzaman O, Wahner-Roedler DL, Malek RS, Sebo TJ, Li CY, Kyle RA: Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc. 2000, 75: 1264-1268. 10.4065\/75.12.1264.","journal-title":"Mayo Clin Proc"},{"key":"412_CR82","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","volume":"10","author":"PT Sattianayagam","year":"2010","unstructured":"Sattianayagam PT, Gibbs SD, Pinney JH, Wechalekar AD, Lachmann HJ, Whelan CJ, Gilbertson JA, Hawkins PN, Gillmore JD: Solid organ transplantation in AL amyloidosis. Am J Transplant. 2010, 10: 2124-2131. 10.1111\/j.1600-6143.2010.03227.x.","journal-title":"Am J Transplant"},{"key":"412_CR83","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.acvd.2008.06.018","volume":"101","author":"A Mignot","year":"2008","unstructured":"Mignot A, Varnous S, Redonnet M, Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, Boissonnat P, Gandjbakhch I, Herpin D, Touchard G, Bridoux F: Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis. 2008, 101: 523-532. 10.1016\/j.acvd.2008.06.018.","journal-title":"Arch Cardiovasc Dis"},{"key":"412_CR84","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","volume":"26","author":"SM Herrmann","year":"2011","unstructured":"Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N: Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant. 2011, 26: 2032-2036. 10.1093\/ndt\/gfr067.","journal-title":"Nephrol Dial Transplant"},{"key":"412_CR85","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/ndt\/gfr191","volume":"26","author":"F Bridoux","year":"2011","unstructured":"Bridoux F, Ronco P, Gillmore J, Fermand JP: Renal transplantation in light chain amyloidosis: coming out of the cupboard. Nephrol Dial Transplant. 2011, 26: 1766-1768. 10.1093\/ndt\/gfr191.","journal-title":"Nephrol Dial Transplant"},{"key":"412_CR86","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1365-2141.2004.04970.x","volume":"125","author":"Guidelines Working Group of UK Myeloma Forum","year":"2004","unstructured":"Guidelines Working Group of UK Myeloma Forum: British Commitee for Standards in Haematology, British Society for Haematology: Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004, 125: 681-700.","journal-title":"Br J Haematol"},{"key":"412_CR87","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2002-06-1698","volume":"101","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Greipp PR, Gertz MA, Rajkumar SV: Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood. 2003, 101: 827-830. 10.1182\/blood-2002-06-1698.","journal-title":"Blood"},{"key":"412_CR88","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1365-2559.2007.02658.x","volume":"50","author":"RP Hasserjian","year":"2007","unstructured":"Hasserjian RP, Goodman HJB, Lachmann HJ, Muzikansky A, Hawkins PN: Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis. Histopathology. 2007, 50: 567-573. 10.1111\/j.1365-2559.2007.02658.x.","journal-title":"Histopathology"},{"key":"412_CR89","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/417254a","volume":"417","author":"MB Pepys","year":"2002","unstructured":"Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN: Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 2002, 417: 254-259. 10.1038\/417254a.","journal-title":"Nature"},{"key":"412_CR90","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature09494","volume":"468","author":"K Bodin","year":"2010","unstructured":"Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB: Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010, 468: 93-97. 10.1038\/nature09494.","journal-title":"Nature"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1172-7-54.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:16:37Z","timestamp":1630527397000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/1750-1172-7-54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,21]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["412"],"URL":"https:\/\/doi.org\/10.1186\/1750-1172-7-54","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,21]]},"assertion":[{"value":"4 May 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"54"}}